NASDAQ:RENB

Renovaro (RENB) Stock Price, News & Analysis

$1.25
-0.21 (-14.04%)
(As of 01:02 PM ET)
Today's Range
$1.25
$1.48
50-Day Range
$1.47
$3.23
52-Week Range
$0.39
$5.25
Volume
84,495 shs
Average Volume
296,007 shs
Market Capitalization
$180.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RENB stock logo

About Renovaro Stock (NASDAQ:RENB)

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

RENB Stock Price History

RENB Stock News Headlines

Renovaro (NASDAQ:RENB) Trading 0.7% Higher
1970’s computer coder Issues Shocking AI Warning
Louis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.
1970’s computer coder Issues Shocking AI Warning
Louis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology… Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.
Renovaro Shareholder Notice
Renovaro Shareholder Alert
RENB Apr 2024 2.500 call
Renovaro Ongoing Investor Alert
Renovaro Biosciences Inc.: Statement of Renovaro Inc
Statement of Renovaro Inc
Statement of Renovaro Inc
See More Headlines
Receive RENB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
5/09/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RENB
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-39,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.80 per share

Miscellaneous

Free Float
112,463,000
Market Cap
$180.30 million
Optionable
Optionable
Beta
0.44
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Hon. Mark R. Dybul M.D. (Age 60)
    CEO, Director & Member of HBV Scientific Advisory Board
    Comp: $764.58k
  • Dr. Francois Binette M.Sc. (Age 60)
    Ph.D., COO and Executive VP for Research & Development
    Comp: $504.38k
  • Dr. Serhat Gümrükcü
    Co-Founder & Inventor
  • Mr. Simon Tarsh (Age 62)
    Interim Chief Financial Officer
  • Mr. Greg Duczynski Ph.D.
    Senior Vice President for Clinical Operations

RENB Stock Analysis - Frequently Asked Questions

How have RENB shares performed in 2024?

Renovaro's stock was trading at $3.17 at the beginning of 2024. Since then, RENB stock has decreased by 53.9% and is now trading at $1.46.
View the best growth stocks for 2024 here
.

Are investors shorting Renovaro?

Renovaro saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,320,000 shares, an increase of 90.2% from the March 15th total of 1,220,000 shares. Based on an average daily trading volume, of 295,300 shares, the days-to-cover ratio is currently 7.9 days. Currently, 2.3% of the shares of the stock are sold short.
View Renovaro's Short Interest
.

When is Renovaro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our RENB earnings forecast
.

How were Renovaro's earnings last quarter?

Renovaro Inc. (NASDAQ:RENB) issued its quarterly earnings results on Wednesday, February, 14th. The company reported ($0.07) EPS for the quarter.

What ETF holds Renovaro's stock?

Amplify Treatments, Testing and Advancements ETF holds 33,976 shares of RENB stock, representing 0.50% of its portfolio.

Who are Renovaro's major shareholders?

Renovaro's stock is owned by many different retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.01%).

How do I buy shares of Renovaro?

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RENB) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners